Gliclada

Gliclada

gliclazide

Manufacturer:

KRKA

Distributor:

Pahang Pharmacy
Concise Prescribing Info
Contents
Gliclazide
Indications/Uses
Type 2 NIDDM in adults when dietary measures, physical exercise & wt loss alone are insufficient to control blood glucose.
Dosage/Direction for Use
Initially 30 mg daily, may be increased to 60, 90, 120 mg daily in successive steps w/ 1-mth interval. Max: 120 mg daily. Switching from gliclazide 80 mg 1 tab is comparable to 1 tab gliclazide MR 30 mg. Switching from another oral antidiabetic agent Initially 30 mg daily.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to gliclazide, other sulphonylureas & sulphonamides. Type 1 diabetes, diabetic pre-coma & coma, diabetic ketoacidosis. Concomitant use w/ miconazole. Severe renal or hepatic insufficiency. Lactation.
Special Precautions
Hypoglycaemia, malnutrition, irregular mealtimes, skipping meals, fasting or dietary changes, imbalance between physical exercise & carbohydrate intake, overdosage; certain endocrine disorders eg, thyroid disorders, hypopituitarism, hypothyroidism, adrenal insufficiency; dysglycaemia. severe CHD & carotid impairment, diffuse vascular disease, prolonged or high-dose corticosteroid therapy. Regularly monitor blood glucose & glycated Hb levels. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Renal or severe hepatic insufficiency. Pregnancy. Childn & adolescents. Elderly.
Adverse Reactions
Headache, intense hunger, nausea, vomiting, lassitude, drowsiness, sleep disorders, agitation, aggression, poor concentration, reduced awareness & slowed reactions, depression, confusion, visual or speech disorders, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness & loss of consciousness; sweating, clammy skin, anxiety, tachycardia, HTN, palpitations, angina pectoris & cardiac arrhythmias; transient visual disturbances.
Drug Interactions
Increased hypoglycaemic effect w/ miconazole, phenylbutazone. Increased hypoglycaemic reaction w/ alcohol. Potentiated blood glucose-lowering effect w/ other antidiabetics (eg, insulins, acarbose, metformin, thiazolidinediones, dipeptidylpeptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (eg, captopril, enalapril), H2-receptor antagonists, MAOIs, sulphonamides, clarithromycin, NSAIDs. Increased blood glucose levels w/ danazol, chlorpromazine, glucocorticoids, tetracosactrin, ritodrine, salbutamol, terbutaline. Decreased exposure by St. John's wort prep. Risk of dysglycaemia w/ fluoroquinolones. Potentiated anticoagulant therapy eg, warfarin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Presentation/Packing
Form
Gliclada MR tab 30 mg
Packing/Price
90's
Form
Gliclada MR tab 60 mg
Packing/Price
90's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in